| Entry |
|
|---|
| Name |
Colesevelam hydrochloride (USAN);
Welchol (TN);
Cholestagel (TN)
|
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
(C3H7N)m. (C3H5ClO)n. (C12H27ClN2)o. (C13H27N)p. xHCl
|
|---|
| Class |
Cardiovascular agent
DG01946 Hypolipidemic agent
DG01945 Bile acid sequestrant
Gastrointestinal agent
DG01945 Bile acid sequestrant
|
|---|
| Remark |
| Product (DG00361): | D03582<US> |
|
|---|
| Efficacy |
Antidiabetic, Antihyperlipidemic, Bile acid sequestrant |
|---|
| Disease |
Primary hyperlipidemia [DS: H01635] Type 2 diabetes mellitus [DS: H00409] |
|---|
| Comment |
bile acid-binding resin
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C10 LIPID MODIFYING AGENTS
C10A LIPID MODIFYING AGENTS, PLAIN
C10AC Bile acid sequestrants
C10AC04 Colesevelam
D03582 Colesevelam hydrochloride (USAN) <US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
Antidiabetic Agents
Colesevelam
D03582 Colesevelam hydrochloride (USAN)
Cardiovascular Agents
Dyslipidemics, Other
Colesevelam
D03582 Colesevelam hydrochloride (USAN)
Drug classes of therapeutic agents [br08360.html]
Hypolipidemic agents
D03582
New drug approvals in the USA [br08319.html]
New Molecular Entity and New Therapeutic Biological Product Approvals
D03582
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03582
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03582
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
